Catalyst Pharmaceuticals, INC.: management transactions · United States · SEC (Form 4)

About Catalyst Pharmaceuticals, INC.

Catalyst Pharmaceuticals, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ under the ticker CPRX. Headquartered in Coral Gables, Florida, United States, Catalyst is a niche specialty pharma group focused on rare diseases and difficult-to-treat disorders. Incorporated in Delaware in 2006, the company evolved from a development-oriented biotech into a commercial-stage business that now derives most of its revenue from marketed products. Catalyst’s business model is centered on in-licensing, acquiring, and commercializing specialized medicines with durable regulatory and commercial advantages. Its flagship product is FIRDAPSE® (amifampridine), approved in the United States for Lambert-Eaton myasthenic syndrome (LEMS) and launched commercially in 2019. The company also markets AGAMREE® (vamorolone), a rare-disease therapy with a pediatric focus, and FYCOMPA® (perampanel), which Catalyst acquired for the U.S. epilepsy market. This portfolio reflects a clear strategy: build value by acquiring immediately commercializable or near-commercial assets in orphan and specialty indications. From a competitive standpoint, Catalyst stands out for its concentrated but differentiated portfolio, supported by deep regulatory, commercial, and distribution expertise in rare diseases. It is not a broad-based large-cap pharma company; rather, it seeks to create shareholder value through focused execution, sales-force optimization, and disciplined product expansion. The company’s geographic footprint remains primarily U.S.-centric, although it has selective international reach through licensing and supply arrangements, including Canada for FIRDAPSE. Recent developments indicate a continued emphasis on commercial execution and portfolio management. SEC filings and company updates show revenue contributions from FIRDAPSE, AGAMREE, and FYCOMPA, along with a 2025 commercial realignment designed to sharpen support for the two key brands. At the same time, FYCOMPA has faced pressure following loss of exclusivity, reinforcing Catalyst’s need to replenish the portfolio with new accretive assets. For investors, CPRX is best viewed as a specialty rare-disease platform with a relatively defensive profile, but one that remains dependent on a small number of key products and on management’s ability to secure and integrate additional commercial assets.